Tiroiditis subaguda y tirotoxicosis posterior a vacuna contra SARS-CoV-2: reporte de 2 casos

Myriam Vanessa Rueda-Galvis; Isabel Cristina Ramírez-Sánchez; Carlos E. Builes-Montaño; Alejandro Vélez-Hoyos

doi:10.36384/01232576.609

Tiroiditis subaguda y tirotoxicosis posterior a vacuna contra SARS-CoV-2: reporte de 2 casos

Translated title of the contribution: Subacute thyroiditis and thyrotoxicosis after SARS-CoV-2 vaccine: report of 2 cases

Myriam Vanessa Rueda-Galvis, Isabel Cristina Ramírez-Sánchez, Carlos E. Builes-Montaño, Alejandro Vélez-Hoyos

Research output: Contribution to journal › Article in an indexed scientific journal › peer-review

Abstract

The SARS-CoV-2 coronavirus disease which emerged in 2019 (COVID-19), has forced the rapid development of vaccines to prevent the spread of infection and attempt to control the pandemic. Among the vaccines developed, one of the first to be approved with a new technology in the field of vaccination, was the mRNA (messenger ribonucleic acid) vaccine, with rates of effectiveness close to 95% for the prevention of severe COVID-19 disease. Common adverse events are mild local reactions, but there have been some reports of patients developing sub-acute thyroiditis and thyroid dysfunction after receiving the SARS-CoV-2 vaccine. This article presents two case reports of subacute thyroiditis shortly after receiving the COVID-19 vaccine.

Translated title of the contribution	Subacute thyroiditis and thyrotoxicosis after SARS-CoV-2 vaccine: report of 2 cases
Original language	Spanish
Pages (from-to)	383-389
Number of pages	7
Journal	Medicina y Laboratorio
Volume	26
Issue number	4
DOIs	https://doi.org/10.36384/01232576.609
State	Published - 2022
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2022, Universidad de Antioquia. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.36384/01232576.609

Cite this

@article{ac308b7a712248f38f8d54448f8ff2ef,

title = "Tiroiditis subaguda y tirotoxicosis posterior a vacuna contra SARS-CoV-2: reporte de 2 casos",

abstract = "The SARS-CoV-2 coronavirus disease which emerged in 2019 (COVID-19), has forced the rapid development of vaccines to prevent the spread of infection and attempt to control the pandemic. Among the vaccines developed, one of the first to be approved with a new technology in the field of vaccination, was the mRNA (messenger ribonucleic acid) vaccine, with rates of effectiveness close to 95% for the prevention of severe COVID-19 disease. Common adverse events are mild local reactions, but there have been some reports of patients developing sub-acute thyroiditis and thyroid dysfunction after receiving the SARS-CoV-2 vaccine. This article presents two case reports of subacute thyroiditis shortly after receiving the COVID-19 vaccine.",

keywords = "COVID-19, adenovirus, goiter, messenger RNA, thyroiditis, vaccine",

author = "Rueda-Galvis, {Myriam Vanessa} and Ram{\'i}rez-S{\'a}nchez, {Isabel Cristina} and Builes-Monta{\~n}o, {Carlos E.} and Alejandro V{\'e}lez-Hoyos",

year = "2022",

doi = "10.36384/01232576.609",

language = "Espa{\~n}ol",

volume = "26",

pages = "383--389",

journal = "Medicina y Laboratorio",

issn = "0123-2576",

publisher = "Universidad de Antioquia",

number = "4",

}

TY - JOUR

T1 - Tiroiditis subaguda y tirotoxicosis posterior a vacuna contra SARS-CoV-2

T2 - reporte de 2 casos

AU - Rueda-Galvis, Myriam Vanessa

AU - Ramírez-Sánchez, Isabel Cristina

AU - Builes-Montaño, Carlos E.

AU - Vélez-Hoyos, Alejandro

PY - 2022

Y1 - 2022

N2 - The SARS-CoV-2 coronavirus disease which emerged in 2019 (COVID-19), has forced the rapid development of vaccines to prevent the spread of infection and attempt to control the pandemic. Among the vaccines developed, one of the first to be approved with a new technology in the field of vaccination, was the mRNA (messenger ribonucleic acid) vaccine, with rates of effectiveness close to 95% for the prevention of severe COVID-19 disease. Common adverse events are mild local reactions, but there have been some reports of patients developing sub-acute thyroiditis and thyroid dysfunction after receiving the SARS-CoV-2 vaccine. This article presents two case reports of subacute thyroiditis shortly after receiving the COVID-19 vaccine.

AB - The SARS-CoV-2 coronavirus disease which emerged in 2019 (COVID-19), has forced the rapid development of vaccines to prevent the spread of infection and attempt to control the pandemic. Among the vaccines developed, one of the first to be approved with a new technology in the field of vaccination, was the mRNA (messenger ribonucleic acid) vaccine, with rates of effectiveness close to 95% for the prevention of severe COVID-19 disease. Common adverse events are mild local reactions, but there have been some reports of patients developing sub-acute thyroiditis and thyroid dysfunction after receiving the SARS-CoV-2 vaccine. This article presents two case reports of subacute thyroiditis shortly after receiving the COVID-19 vaccine.

KW - COVID-19

KW - adenovirus

KW - goiter

KW - messenger RNA

KW - thyroiditis

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85159310033&partnerID=8YFLogxK

U2 - 10.36384/01232576.609

DO - 10.36384/01232576.609

M3 - Artículo en revista científica indexada

AN - SCOPUS:85159310033

SN - 0123-2576

VL - 26

SP - 383

EP - 389

JO - Medicina y Laboratorio

JF - Medicina y Laboratorio

IS - 4

ER -

Tiroiditis subaguda y tirotoxicosis posterior a vacuna contra SARS-CoV-2: reporte de 2 casos

Abstract

Bibliographical note

UN SDGs

Access to Document

Fingerprint

Cite this